Baxter International has recalled a nationwide lot of the injectable antibiotic used more than any other to prevent infection during surgery, after cardboard particles were found in the solution.
The company announcement published by the FDA covers Lot LD175708 of Cefazolin in Dextrose Injection, USP, 2 grams per 100 milliliters, in single-dose infusion bags, with an expiration date of February 14, 2027. The lot was distributed across the United States between March 25 and June 30, 2025.
This is not a recall that sends people to their medicine cabinets. Cefazolin premix bags hang on IV poles in operating rooms, emergency departments, and infusion suites. The practical consequence lands on hospital pharmacy inventories and on the antibiotic choices surgical teams make, at a moment when the drug is already listed as being in short supply.
What Was Recalled and Why the Risk Language Is Severe
Most drug recalls involve the correct medicine in a flawed condition. This one involves foreign material inside a product designed to go directly into a vein, which is why the safety language reads the way it does.
Baxter's risk statement says use of the defective product has a reasonable probability of causing pulmonary emboli, meaning blockages in the blood vessels of the lungs, along with occlusions of other blood vessels that can lead to tissue death and organ damage, and phlebitis, which is inflammation of vein walls that may lead to clotting. The statement adds that foreign particles infused intravenously can trigger systemic immune activation, organ dysfunction, and hemolysis, the breakdown of blood cells.
The scope is narrow. One lot, one product code, one expiration date. Hospitals and distributors have been notified and asked to check inventories against the lot number. Baxter's Center for Service can be reached at 888-229-0001 for questions about the recall.
The recall was one of three announced within days. MedicalDaily has separately reported on the nationwide recall of subpotent levothyroxine tablets distributed by Major Pharmaceuticals and on the recall of papaverine hydrochloride injection by American Regent over glass particles. The three are unrelated actions by different companies. What they share is a category of failure that regulators watch closely: manufacturing and quality control problems in products people cannot inspect themselves.
Why This Antibiotic Is Not a Medicine Cabinet Item
Cefazolin is a first-generation cephalosporin, and its role in modern surgery is close to foundational. Clinical guidelines identify it as the preferred first-line agent for surgical prophylaxis, valued for reliable activity against the Gram-positive organisms that cause most surgical site infections, predictable pharmacokinetics, a well-established safety profile, and low cost. It reaches therapeutic tissue concentrations quickly, which matters when the standard is to have the drug on board within 60 minutes of the first incision.
That means the population exposed to this product is large but transient. A patient receives a dose or two around an operation and never thinks about it again. Almost nobody has a bag of it at home.
The exception worth naming is home infusion. A small number of patients receive IV antibiotics through home infusion services, and anyone in that situation who has been receiving cefazolin should contact their infusion provider or prescribing clinician to confirm whether their supply is affected. They should not stop treatment on their own. An interrupted antibiotic course carries its own risk, and the provider can substitute product from an unaffected lot.
The Supply Question Behind the Recall
A single-lot recall would ordinarily be an inventory nuisance. It matters more here because of what the federal shortage data already show.
The FDA drug shortage database lists cefazolin injection with a status of currently in shortage. The drug has moved on and off that list for years. Sterile injectables are difficult to make, only a handful of companies produce cefazolin for the United States market, and a problem at one facility can move national supply.
When cefazolin is unavailable, surgical teams do not simply skip prophylaxis. They substitute, and the substitutes carry their own trade-offs. The peer-reviewed literature on spine surgery notes that vancomycin is frequently used as an empiric first choice in place of cefazolin, exposing patients to delayed infusion times, kidney toxicity, and pressure toward vancomycin-resistant organisms. Broader-spectrum alternatives raise antimicrobial resistance concerns that hospital stewardship programs work specifically to avoid.
Patients with a documented penicillin allergy encounter a related problem. Concern about cross-reactivity often steers them away from cefazolin even when the evidence supports its use, meaning they receive a second-choice agent by default. That is a conversation worth having with a surgical team before a procedure rather than after.
What Patients and Families Should Do
For nearly everyone, the answer is nothing. There is no consumer action tied to this recall, no product to check at home, and no reason to postpone a scheduled operation.
Anyone with surgery coming up who wants reassurance can ask a straightforward question at the pre-operative visit: which antibiotic is planned for prophylaxis, and does the hospital have an adequate supply? Surgical and pharmacy teams track recalls and shortages routinely, and the question is reasonable.
Patients who had surgery between spring 2025 and now and who developed unexplained symptoms afterward, particularly shortness of breath, chest pain, or a painful and inflamed vein at an IV site, should raise it with a clinician. Those symptoms have many causes and are far more likely to reflect something other than this recall, but they warrant evaluation on their own merits.
Adverse reactions or quality problems can be reported to the FDA's MedWatch program.
What Happens Next
The FDA typically assigns a recall classification some weeks after a company announcement, and that classification will indicate how seriously the agency judges the hazard. It had not been posted for this lot as of publication.
Whether the recall affects national cefazolin availability depends on how much of the lot remains in distribution and on how other manufacturers are supplying the market. The FDA shortage database is updated as manufacturers report, and hospital pharmacy groups track availability more granularly than consumers can.
The confirmed finding is that one nationwide lot of Baxter's cefazolin premix was recalled for cardboard particulate, with a risk statement describing possible vessel blockage and vein inflammation. The people most affected are hospital pharmacies managing inventory and the small number of home infusion patients on this drug. The most reasonable action for a surgical patient is a question at the pre-operative visit, not a change of plan. The central uncertainty is whether this recall tightens a supply picture that federal data already describe as constrained.
Frequently Asked Questions
What exactly was recalled? One nationwide lot of Baxter's Cefazolin in Dextrose Injection, USP, 2 grams per 100 milliliters, lot LD175708, expiring February 14, 2027, distributed between March 25 and June 30, 2025.
Why was it recalled? Particulate matter identified as cardboard was found in the solution.
Do I have this drug at home? Almost certainly not. It is a hospital and clinic infusion product. Home infusion patients should contact their provider rather than stop treatment.
Should I postpone my surgery? No. There is no recommendation to delay procedures. You can ask your surgical team which prophylactic antibiotic is planned and whether supply is adequate.
What is cefazolin used for? It is the most commonly used antibiotic for preventing surgical site infections and also treats certain skin, bone, and urinary infections.
Is cefazolin in shortage? The FDA drug shortage database lists cefazolin injection as currently in shortage. It has moved on and off that list over several years.
What symptoms would warrant a call to my doctor? Shortness of breath, chest pain, or a painful, red, swollen vein at a prior IV site. These have many causes and should be evaluated on their own.
